TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
20.94
-0.08 (-0.38%)
As of 2:33PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close20.70
Open20.17
Bid20.92 x 2100
Ask20.93 x 700
Day's Range20.72 - 21.22
52 Week Range10.85 - 37.94
Volume7,733,987
Avg. Volume27,134,538
Market Cap21.275B
Beta0.68
PE Ratio (TTM)N/A
EPS (TTM)-5.87
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-11-27
1y Target Est19.35
Trade prices are not sourced from all markets
  • Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
    Zacks7 hours ago

    Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies

    Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.

  • Behind Novartis’s 4Q17 Estimates: Innovative Medicines
    Market Realistyesterday

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.

  • Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch
    Zacksyesterday

    Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch

    Global markets largely echoed Wall Street's fortunes over last week.

  • Inside Novartis’s 4Q17 Earnings: Analyst Estimates
    Market Realistyesterday

    Inside Novartis’s 4Q17 Earnings: Analyst Estimates

    Novartis’s 4Q17 Earnings: Behind the ExpectationsA look at Novartis’s earnings

  • MarketWatchyesterday

    Teva shares decline on negative late-stage trial results for asthma therapy

    Teva Pharmaceutical Industries Ltd. shares slid 3% premarket Monday, after the company said a late-stage trial of an asthma treatment failed to meet its main goal. The company said the therapy, subcutaneously ...

  • Business Wireyesterday

    Teva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosinophilic Asthma

    Teva Pharmaceutical Industries Ltd., today announced that a Phase III registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint of significantly reducing the frequency of clinical asthma exacerbations in patients with uncontrolled asthma and elevated blood eosinophils >300/mcL.

  • How Hospitals Plan To Put Pressure On Generic-Drug Makers
    Investor's Business Daily5 days ago

    How Hospitals Plan To Put Pressure On Generic-Drug Makers

    Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist6 days ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Daily7 days ago

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realist7 days ago

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacks7 days ago

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realist7 days ago

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • How Teva Pharmaceutical Plans to Optimize Global Generics
    Market Realist7 days ago

    How Teva Pharmaceutical Plans to Optimize Global Generics

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist8 days ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist8 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist8 days ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • Business Wire8 days ago

    Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

    Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved the use of TRISENOX® injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia whose APL is characterized by the presence of the t translocation or PML/RAR-alpha gene expression.

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist8 days ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool10 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These three small biotech stocks saw huge jumps. Can their momentum continue?

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist11 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • A Look at Insys Therapeutics’ Financial Performance
    Market Realist11 days ago

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.

  • MarketWatch11 days ago

    Teva credit rating downgraded to junk status at Moody's

    Teva Pharmaceuticals Industries Ltd.'s credit rating was downgraded two notches into junk status at Moody's Investors Service, which cited concerns over the drug maker's sizable debt. The rating agency ...

  • What Analysts Recommend for Insys Therapeutics and Peers
    Market Realist11 days ago

    What Analysts Recommend for Insys Therapeutics and Peers

    What to Expect from Insys Therapeutics in 2018Company overview

  • Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
    Market Realist11 days ago

    Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.

  • The Key Challenges Teva Pharmaceutical Is Facing
    Market Realist11 days ago

    The Key Challenges Teva Pharmaceutical Is Facing

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.